Key points from article :
Mediwhale, a South Korean health diagnostics firm, has secured $12 million in a Series A2 funding round to enhance its AI-based technology for early detection of chronic and age-related diseases. Founded in 2016, the company leverages AI to analyze standard retinal images, making it easier to identify diseases like cardiovascular conditions and chronic kidney disease in primary care settings.
The company's Reti-Intelligence platform processes retinal images to generate quick results, boasting a sensitivity of 92% and specificity of 95%. Its flagship product, Reti-CVD, offers a non-invasive alternative for predicting cardiovascular risk and has already been widely used in Korea following reimbursement approval.
With the new funding, Mediwhale plans to improve its AI algorithms and expand its product offerings. The company is also pursuing FDA approval for Reti-CVD in the U.S., aiming to establish a strong presence in the global market for cardiovascular and metabolic disease management.
